Selected research
Industry Research
Endocrine Disruptor Testing Industry Research Report 2026
Market perspective
The global Endocrine Disruptor Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Endocrine Disruptor Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Endocrine Disruptor Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Endocrine Disruptor Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Endocrine Disruptor Testing include Charles River Laboratories, Labcorp, Eurofins Scientific, PerkinElmer, Intertek, Smithers, LAUS, Xenometrix and ToxStrategies, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Endocrine Disruptor Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Endocrine Disruptor Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Endocrine Disruptor Testing Market by Company
Charles River Laboratories
Labcorp
Eurofins Scientific
PerkinElmer
Intertek
Smithers
LAUS
Xenometrix
ToxStrategies
Fera Science
Compliance Services International
Staphyt
Creative Proteomics
Creative Bioarray
Endocrine Disruptor Testing Segment by Type
In Vitro (Cell-based) Testing
In Vivo (Animal) Testing
In Silico (Computational) Modeling
Others
Endocrine Disruptor Testing Segment by Application
Environmental Monitoring
Food Safety
Cosmetics and Personal Care Products
Public Health and Disease Prevention
Others
Endocrine Disruptor Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endocrine Disruptor Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endocrine Disruptor Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endocrine Disruptor Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Endocrine Disruptor Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- In Vitro (Cell-based) Testing
- In Vivo (Animal) Testing
- In Silico (Computational) Modeling
- Others
Applications
- Environmental Monitoring
- Food Safety
- Cosmetics and Personal Care Products
- Public Health and Disease Prevention
- Others
Companies covered
- Charles River Laboratories
- Labcorp
- Eurofins Scientific
- PerkinElmer
- Intertek
- Smithers
- LAUS
- Xenometrix
- ToxStrategies
- Fera Science
- Compliance Services International
- Staphyt
- Creative Proteomics
- Creative Bioarray
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Endocrine Disruptor Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 In Vitro (Cell-based) Testing
- 2.2.3 In Vivo (Animal) Testing
- 2.2.4 In Silico (Computational) Modeling
- 2.2.5 Others
- 2.3 Endocrine Disruptor Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Environmental Monitoring
- 2.3.3 Food Safety
- 2.3.4 Cosmetics and Personal Care Products
- 2.3.5 Public Health and Disease Prevention
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Endocrine Disruptor Testing Breakdown Data by Type
- 3.1 Global Endocrine Disruptor Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Endocrine Disruptor Testing Forecasted Market Size by Type (2027-2032)
4 Endocrine Disruptor Testing Breakdown Data by Application
- 4.1 Global Endocrine Disruptor Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Endocrine Disruptor Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Endocrine Disruptor Testing Market Perspective (2021-2032)
- 5.2 Global Endocrine Disruptor Testing Growth Trends by Region
- 5.2.1 Global Endocrine Disruptor Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Endocrine Disruptor Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Endocrine Disruptor Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Endocrine Disruptor Testing Market Dynamics
- 5.3.1 Endocrine Disruptor Testing Industry Trends
- 5.3.2 Endocrine Disruptor Testing Market Drivers
- 5.3.3 Endocrine Disruptor Testing Market Challenges
- 5.3.4 Endocrine Disruptor Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Endocrine Disruptor Testing Players by Revenue
- 6.1.1 Global Top Endocrine Disruptor Testing Players by Revenue (2021-2026)
- 6.1.2 Global Endocrine Disruptor Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Endocrine Disruptor Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Endocrine Disruptor Testing Head Office and Area Served
- 6.4 Global Endocrine Disruptor Testing Players, Product Type & Application
- 6.5 Global Endocrine Disruptor Testing Manufacturers Established Date
- 6.6 Global Endocrine Disruptor Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Endocrine Disruptor Testing Market Size (2021-2032)
- 7.2 North America Endocrine Disruptor Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Endocrine Disruptor Testing Market Size by Country (2021-2026)
- 7.4 North America Endocrine Disruptor Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Endocrine Disruptor Testing Market Size (2021-2032)
- 8.2 Europe Endocrine Disruptor Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Endocrine Disruptor Testing Market Size by Country (2021-2026)
- 8.4 Europe Endocrine Disruptor Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Endocrine Disruptor Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Endocrine Disruptor Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Endocrine Disruptor Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Endocrine Disruptor Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Endocrine Disruptor Testing Market Size (2021-2032)
- 10.2 South America Endocrine Disruptor Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Endocrine Disruptor Testing Market Size by Country (2021-2026)
- 10.4 South America Endocrine Disruptor Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Endocrine Disruptor Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Endocrine Disruptor Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Endocrine Disruptor Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Endocrine Disruptor Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Charles River Laboratories
- 12.1.1 Charles River Laboratories Company Information
- 12.1.2 Charles River Laboratories Business Overview
- 12.1.3 Charles River Laboratories Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.1.4 Charles River Laboratories Endocrine Disruptor Testing Product Portfolio
- 12.1.5 Charles River Laboratories Recent Developments
- 12.2 Labcorp
- 12.2.1 Labcorp Company Information
- 12.2.2 Labcorp Business Overview
- 12.2.3 Labcorp Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.2.4 Labcorp Endocrine Disruptor Testing Product Portfolio
- 12.2.5 Labcorp Recent Developments
- 12.3 Eurofins Scientific
- 12.3.1 Eurofins Scientific Company Information
- 12.3.2 Eurofins Scientific Business Overview
- 12.3.3 Eurofins Scientific Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.3.4 Eurofins Scientific Endocrine Disruptor Testing Product Portfolio
- 12.3.5 Eurofins Scientific Recent Developments
- 12.4 PerkinElmer
- 12.4.1 PerkinElmer Company Information
- 12.4.2 PerkinElmer Business Overview
- 12.4.3 PerkinElmer Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.4.4 PerkinElmer Endocrine Disruptor Testing Product Portfolio
- 12.4.5 PerkinElmer Recent Developments
- 12.5 Intertek
- 12.5.1 Intertek Company Information
- 12.5.2 Intertek Business Overview
- 12.5.3 Intertek Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.5.4 Intertek Endocrine Disruptor Testing Product Portfolio
- 12.5.5 Intertek Recent Developments
- 12.6 Smithers
- 12.6.1 Smithers Company Information
- 12.6.2 Smithers Business Overview
- 12.6.3 Smithers Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.6.4 Smithers Endocrine Disruptor Testing Product Portfolio
- 12.6.5 Smithers Recent Developments
- 12.7 LAUS
- 12.7.1 LAUS Company Information
- 12.7.2 LAUS Business Overview
- 12.7.3 LAUS Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.7.4 LAUS Endocrine Disruptor Testing Product Portfolio
- 12.7.5 LAUS Recent Developments
- 12.8 Xenometrix
- 12.8.1 Xenometrix Company Information
- 12.8.2 Xenometrix Business Overview
- 12.8.3 Xenometrix Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.8.4 Xenometrix Endocrine Disruptor Testing Product Portfolio
- 12.8.5 Xenometrix Recent Developments
- 12.9 ToxStrategies
- 12.9.1 ToxStrategies Company Information
- 12.9.2 ToxStrategies Business Overview
- 12.9.3 ToxStrategies Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.9.4 ToxStrategies Endocrine Disruptor Testing Product Portfolio
- 12.9.5 ToxStrategies Recent Developments
- 12.10 Fera Science
- 12.10.1 Fera Science Company Information
- 12.10.2 Fera Science Business Overview
- 12.10.3 Fera Science Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.10.4 Fera Science Endocrine Disruptor Testing Product Portfolio
- 12.10.5 Fera Science Recent Developments
- 12.11 Compliance Services International
- 12.11.1 Compliance Services International Company Information
- 12.11.2 Compliance Services International Business Overview
- 12.11.3 Compliance Services International Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.11.4 Compliance Services International Endocrine Disruptor Testing Product Portfolio
- 12.11.5 Compliance Services International Recent Developments
- 12.12 Staphyt
- 12.12.1 Staphyt Company Information
- 12.12.2 Staphyt Business Overview
- 12.12.3 Staphyt Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.12.4 Staphyt Endocrine Disruptor Testing Product Portfolio
- 12.12.5 Staphyt Recent Developments
- 12.13 Creative Proteomics
- 12.13.1 Creative Proteomics Company Information
- 12.13.2 Creative Proteomics Business Overview
- 12.13.3 Creative Proteomics Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.13.4 Creative Proteomics Endocrine Disruptor Testing Product Portfolio
- 12.13.5 Creative Proteomics Recent Developments
- 12.14 Creative Bioarray
- 12.14.1 Creative Bioarray Company Information
- 12.14.2 Creative Bioarray Business Overview
- 12.14.3 Creative Bioarray Revenue in Endocrine Disruptor Testing Business (2021-2026)
- 12.14.4 Creative Bioarray Endocrine Disruptor Testing Product Portfolio
- 12.14.5 Creative Bioarray Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst